Re­gen­eron and Genen­tech bat­tle for oph­thal­mol­o­gists’ affin­i­ty in Eylea HD, Vabysmo matchup

Af­ter sev­en months on the mar­ket, Re­gen­eron’s Eylea HD is al­ready mak­ing strides with oph­thal­mol­o­gists.

Ac­cord­ing to Spher­ix Glob­al In­sights’ re­search, 81% of oph­thal­mol­o­gists who …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.